Results from the phase III 006 Study of Cytalux (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer reports that use of Cytalux during ovarian cancer surgery demonstrated identification of additional lesions that were not identified with conventional means and not otherwise planned for resection.
FDA has issued a safety alert informing patients and providers about reports of squamous cell carcinoma and various lymphomas located in the capsule or scar tissue around breast implants. After an initial extensive review, we currently believe that the risk of SCC and other lymphomas occurring in the tissue around breast implants is rare.
Roche’s VENTANA PD-L1 (SP263) Assay has received CE IVD approval to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo, based on results of the phase III EMPOWER-Lung 1.
MD Anderson Cancer Center announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies.
OU Health Stephenson Cancer Center joined Caris’ Precision Oncology Alliance, a network of 70 cancer institutions committed to utilizing clinical data to advance patient care and outcomes.
Strata Oncology Inc announced the integration of discrete genomic data from its StrataNGS NGS-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module.
Indivumed GmbH and CELLphenomics GmbH have formed a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets.
Augusto C. Ochoa’s introduction to NCI community research had the feel of a battlefield commission. In the aftermath of the 2005 Hurricane Katrina, the PI of what was then the Community Clinical Oncology Program informed Ochoa, that she would be leaving Louisiana State University.
European regulators have prohibited the already-implemented $7.1 billion merger of Illumina and GRAIL, stating that the deal “would have stifled innovation, and reduced choice in the emerging market for blood-based early cancer detection tests.”
As NCI prepares for a transition of leadership, Acting Director Douglas Lowy is setting out an agenda focused on multi-cancer detection tests, undruggable targets, cell therapy, and on eliminating disparities caused by persistent poverty.
